RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arcturus Therapeutics Holdings Stock

Arcturus Therapeutics Holdings Liabilities 2024

Arcturus Therapeutics Holdings Liabilities

150.89 M USD

Ticker

ARCT

ISIN

US03969T1097

WKN

A2PMAS

In 2024, Arcturus Therapeutics Holdings's total liabilities amounted to 150.89 M USD, a -16.22% difference from the 180.1 M USD total liabilities in the previous year.

Arcturus Therapeutics Holdings Aktienanalyse

What does Arcturus Therapeutics Holdings do?

Arcturus Therapeutics is a biopharmaceutical company based in San Diego, California, founded in 2013. The company specializes in the development of RNA-based therapeutics and has developed a proprietary technology platform called "LUNAR" that enables safe and effective transport of RNA molecules into target cells. The technology, resulting from over a decade of research and development, allows for the development of drugs for a variety of diseases. Arcturus's business model focuses on forming partnerships with other pharmaceutical companies to accelerate the development of RNA-based therapeutics. The company collaborates with partners from various industries, ranging from large biotech companies to small startups, in order to promote the development of effective treatments. Arcturus also has its own pipeline of therapeutics in development. The company has formed partnerships with Janssen Pharmaceuticals, Takeda Pharmaceutical, Ultragenyx Pharmaceutical, and CureVac. Arcturus's pipeline includes a variety of therapeutics targeting different therapy areas, including oncology, critical care, and rare diseases. A key focus is on the treatment of liver diseases such as hemophilia B, alpha-1 antitrypsin deficiency, and factor VIII deficiency. Arcturus is also working on therapies for rare diseases like lysosomal storage disease and other diseases such as diabetes, kidney disease, and AIDS. One important product from Arcturus is the hepatitis B vaccine candidate, developed in partnership with Janssen Pharmaceuticals. The vaccine candidate utilizes Arcturus's LUNAR technology to generate an effective immune response against hepatitis B. Phase 2 studies of the vaccine have shown promising results, suggesting that the vaccine can play a significant role in combating hepatitis B. Another important product from Arcturus is ARO-AAT, developed for the treatment of alpha-1 antitrypsin deficiency. Deficiency of this protein can lead to liver and lung diseases, and currently there is no effective treatment method. ARO-AAT utilizes Arcturus's LUNAR technology to effectively transport RNA molecules to the affected cells. Clinical studies of ARO-AAT have been positively evaluated thus far. Arcturus also has plans to apply its RNA technology in the field of vaccine development, aiming to quickly and effectively respond to future pandemics and threats of infectious diseases. In summary, Arcturus Therapeutics is a biopharmaceutical company that has developed a proprietary RNA technology platform called LUNAR to develop safe and effective therapeutics for a variety of diseases. The company collaborates with a variety of partners to accelerate the development of RNA-based therapeutics. Arcturus has its own pipeline of therapeutics in development, including a hepatitis B vaccine candidate and ARO-AAT for the treatment of alpha-1 antitrypsin deficiency. The company also has plans to utilize its RNA technology for vaccine development to quickly and effectively respond to future infectious diseases. Arcturus Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Arcturus Therapeutics Holdings's Liabilities

Arcturus Therapeutics Holdings's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Arcturus Therapeutics Holdings's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Arcturus Therapeutics Holdings's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Arcturus Therapeutics Holdings's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Arcturus Therapeutics Holdings’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Arcturus Therapeutics Holdings stock

What is the level of liabilities of Arcturus Therapeutics Holdings this year?

Arcturus Therapeutics Holdings has a debt balance of 150.89 M USD this year.

What were the liabilities of Arcturus Therapeutics Holdings compared to the previous year?

The liabilities of Arcturus Therapeutics Holdings have increased by -16.22% dropped compared to the previous year.

What are the consequences of high debt for investors of Arcturus Therapeutics Holdings?

High liabilities can pose a risk for investors of Arcturus Therapeutics Holdings, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Arcturus Therapeutics Holdings?

Low liabilities mean that Arcturus Therapeutics Holdings has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Arcturus Therapeutics Holdings affect the company?

An increase in liabilities of Arcturus Therapeutics Holdings can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Arcturus Therapeutics Holdings affect the company?

A decrease in the liabilities of Arcturus Therapeutics Holdings can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Arcturus Therapeutics Holdings?

Some factors that can influence the liabilities of Arcturus Therapeutics Holdings include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Arcturus Therapeutics Holdings so important for investors?

The liabilities of Arcturus Therapeutics Holdings are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Arcturus Therapeutics Holdings take to modify the liabilities?

To change its liabilities, Arcturus Therapeutics Holdings can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Arcturus Therapeutics Holdings pay?

Over the past 12 months, Arcturus Therapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arcturus Therapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Arcturus Therapeutics Holdings?

The current dividend yield of Arcturus Therapeutics Holdings is .

When does Arcturus Therapeutics Holdings pay dividends?

Arcturus Therapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Arcturus Therapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arcturus Therapeutics Holdings located?

Arcturus Therapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arcturus Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arcturus Therapeutics Holdings from 9/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.

When did Arcturus Therapeutics Holdings pay the last dividend?

The last dividend was paid out on 9/17/2024.

What was the dividend of Arcturus Therapeutics Holdings in the year 2023?

In the year 2023, Arcturus Therapeutics Holdings distributed 0 USD as dividends.

In which currency does Arcturus Therapeutics Holdings pay out the dividend?

The dividends of Arcturus Therapeutics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Arcturus Therapeutics Holdings

Our stock analysis for Arcturus Therapeutics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arcturus Therapeutics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.